DBV Technologies (NASDAQ:DBVT) Shares Pass Above 50-Day Moving Average - What's Next?

Key Points

• DBV Technologies' share price has recently surpassed its 50-day moving average of $9.67, trading as high as $10.08 before closing at $9.75.
• Analyst ratings for DBV Technologies show a consensus of "Moderate Buy" with a target price of $14.75, while one analyst has rated it "Sell."
• The company reported a significant earnings miss in its latest quarterly results, with an EPS of ($1.55) compared to expectations of ($0.21), alongside a revenue of $1.74 million.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $9.67 and traded as high as $10.08. DBV Technologies shares last traded at $9.75, with a volume of 12,807 shares.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on DBVT. The Goldman Sachs Group raised DBV Technologies to a "sell" rating and set a $7.25 price target on the stock in a research note on Thursday, May 29th. Wall Street Zen cut DBV Technologies from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. JMP Securities reissued a "market outperform" rating and issued a $21.00 price target on shares of DBV Technologies in a research note on Thursday, June 26th. Lifesci Capital raised DBV Technologies to a "strong-buy" rating in a research note on Thursday, June 26th. Finally, Citigroup reissued an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, DBV Technologies has an average rating of "Moderate Buy" and an average price target of $14.75.

DBV Technologies Trading Down 0.9%

The company has a fifty day moving average of $9.62 and a two-hundred day moving average of $8.68. The stock has a market capitalization of $260.30 million, a price-to-earnings ratio of -1.99 and a beta of -0.36.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported ($1.55) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.34). DBV Technologies had a negative return on equity of 287.15% and a negative net margin of 3,220.49%.The company had revenue of $1.74 million during the quarter, compared to analyst estimates of $0.64 million. As a group, sell-side analysts predict that DBV Technologies S.A. will post -7.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Vivo Capital LLC acquired a new position in shares of DBV Technologies during the second quarter worth approximately $9,659,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of DBV Technologies during the 2nd quarter worth approximately $9,659,000. MPM Bioimpact LLC acquired a new stake in shares of DBV Technologies during the 2nd quarter worth approximately $9,649,000. Octagon Capital Advisors LP acquired a new stake in shares of DBV Technologies during the 2nd quarter worth approximately $9,315,000. Finally, Nan Fung Trinity HK Ltd. acquired a new stake in shares of DBV Technologies during the 2nd quarter worth approximately $340,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.